Abstract
The French contract pharmaceutical services firm Seqens has opened a 1,400 m 2 research and development center in Devens, Massachusetts. The $5 million facility, located near Boston, is intended to accelerate the firm’s development of active pharmaceutical ingredients and excipients, including lipids used in the manufacture of mRNA vaccines for COVID-19. The center replaces a smaller lab in Devens. Employees will transfer to the new center, where Seqens expects to double the number of scientists by 2026. Asymchem, a Chinese contract pharmaceutical services firm, plans to open a research center in nearby Woburn in the first quarter of this year.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
